Found: 12
Select item for more details and to access through your institution.
Loss of seroprotective antibody after a full series of hepatitis A virus vaccination in people with HIV.
- Published in:
- Hepatology Research, 2024, v. 54, n. 5, p. 417, doi. 10.1111/hepr.14044
- By:
- Publication type:
- Article
Natural killer group 2D‐major histocompatibility complex class I polypeptide‐related sequence A activation enhances natural killer cell‐mediated immunity against hepatocellular carcinoma: A review.
- Published in:
- Hepatology Research, 2024, v. 54, n. 5, p. 420, doi. 10.1111/hepr.14038
- By:
- Publication type:
- Article
Editorial for "A new imaging classification for safer radial access visceral intervention of the liver and optimal case selection: A preliminary report".
- Published in:
- Hepatology Research, 2024, v. 54, n. 5, p. 415, doi. 10.1111/hepr.14037
- By:
- Publication type:
- Article
Reply to Letter to the Editor: "Patients with uncertain advanced fibrosis and cirrhosis diagnosis by Agile3+ and Agile4 scores cannot be excluded in validation studies".
- Published in:
- Hepatology Research, 2024, v. 54, n. 5, p. 497, doi. 10.1111/hepr.14023
- By:
- Publication type:
- Article
Attenuation of hepatitis A antibody after immunization with hepatitis A vaccine (Aimmugen) in people living with HIV.
- Published in:
- Hepatology Research, 2024, v. 54, n. 5, p. 487, doi. 10.1111/hepr.14012
- By:
- Publication type:
- Article
A new imaging classification for safer radial access visceral intervention of the liver and optimal case selection: A preliminary report.
- Published in:
- Hepatology Research, 2024, v. 54, n. 5, p. 479, doi. 10.1111/hepr.13998
- By:
- Publication type:
- Article
Patients with uncertain advanced fibrosis and cirrhosis diagnosis by Agile3+ and Agile4 scores cannot be excluded in validation studies.
- Published in:
- Hepatology Research, 2024, v. 54, n. 5, p. 495, doi. 10.1111/hepr.13996
- By:
- Publication type:
- Article
Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.
- Published in:
- Hepatology Research, 2024, v. 54, n. 5, p. 451, doi. 10.1111/hepr.13995
- By:
- Publication type:
- Article
Metabolic dysfunction‐associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis.
- Published in:
- Hepatology Research, 2024, v. 54, n. 5, p. 429, doi. 10.1111/hepr.13994
- By:
- Publication type:
- Article
Cost‐effectiveness analysis of adult living‐donor liver transplantation in Japan.
- Published in:
- Hepatology Research, 2024, v. 54, n. 5, p. 465, doi. 10.1111/hepr.13992
- By:
- Publication type:
- Article
The impact of the COVID‐19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan: A multicenter collaborative observational study.
- Published in:
- Hepatology Research, 2024, v. 54, n. 5, p. 439, doi. 10.1111/hepr.13990
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Hepatology Research, 2024, v. 54, n. 5, p. 413, doi. 10.1111/hepr.13917
- Publication type:
- Article